Sponsor · clinical trials

AstraZeneca clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine and the EU Clinical Trials Information System (CTIS) — current trials in our USA, China, Spain, South Korea, UK, Japan, Canada, Germany, Italy, France, Taiwan, Poland, Brazil, Australia, Turkey, India, Belgium, Netherlands, Israel, Mexico, Denmark, Austria, Czechia, Sweden, Portugal, Switzerland, Singapore, Norway, Egypt, Ireland and EU (CTIS) registers with AstraZeneca as lead sponsor. Synced 10 Nov 2026

479Current trials

229Recruiting now

206Drugs in these trials

31Trial registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Synced 10 Nov 2026 · Editorial standards

At a glance

AstraZeneca is the lead sponsor of 479 current clinical trials in our USA, China, Spain, South Korea, UK, Japan, Canada, Germany, Italy, France, Taiwan, Poland, Brazil, Australia, Turkey, India, Belgium, Netherlands, Israel, Mexico, Denmark, Austria, Czechia, Sweden, Portugal, Switzerland, Singapore, Norway, Egypt, Ireland and EU (CTIS) registers. 229 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Durvalumab, Carboplatin and Cisplatin. The most-studied condition is Breast Cancer.

Company profile on this site (news, sites, medicines, approvals): AstraZeneca (GB) →

ClinicalTrials.gov trials by status

Recruiting22950%
Not yet open92%
Active, closed21547%
By invitation10%

Trials by phase

Phase 317138%
Observational10824%
Phase 26214%
Phase 14911%
Phase 1/24510%
Phase 4112%
Not applicable72%
Phase 2/310%

Clinical trials sponsored by AstraZeneca

454 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA NCT06927648 · ClinicalTrials.gov ↗ · Breast Cancer	Observational	Recruiting	2025-10	South Korea
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody NCT07285213 · Clostridioides Difficile Infection	Phase 2	Recruiting	2025-12	UK, USA, Germany, France, Spain, Italy, Sweden, Denmark, Poland, Canada, Japan, Australia
RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil NCT06491862 · ClinicalTrials.gov ↗ · Non-squamous Non-Small Cell Lung Cancer	Observational	Recruiting	2024-07	Brazil
Real-World Treatment Study of Koselugo (Selumetinib) NCT06360406 · ClinicalTrials.gov ↗ · Neurofibromatosis 1, Neurofibroma, Plexiform	Observational	Recruiting	2024-06	South Korea
Minimally Interventional Study on Prevalence of Emerging ESR1 Mutations in Liquid Biopsy in Three Cohorts of Patients With Breast Cancer in Comparison With Patient's Baseline ESR1 Mutation Status as Defined by Tissue Profiling. NCT06417801 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer	Observational	Recruiting	2024-06	Brazil
An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia NCT03813407 · Hyperkalaemia Drug: Pumitamig	Phase 3	Recruiting	2019-04	UK, USA, India, China, Germany, Spain, Poland, Canada, Brazil, Japan
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus NCT07776509 · Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2 Drug: Lenbelintide	Phase 3	Recruiting	2026-08	UK, USA, China, Sweden, Denmark, Turkey, Canada, Brazil, Japan, Israel
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs NCT05663515 · Pancreatic Cancer Drug: Exenatide	Observational	Recruiting	2024-09	UK, France, Spain, Sweden, Denmark, Norway
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation NCT06952803 · Prostate Cancer Drugs: Abiraterone, Prednisolone/prednisone, Saruparib	Phase 3	Recruiting	2025-08	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors NCT06535607 · Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy) Drugs: Adrucil, Carboplatin, Cisplatin	Phase 2	Recruiting	2024-08	UK, USA, China, Germany, Italy, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC NCT04686305 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer Drugs: Carboplatin, Cisplatin, Durvalumab	Phase 1	Recruiting	2021-03	USA, China, France, Spain, Italy, Netherlands, Belgium, Poland, Turkey, Canada, Brazil, South Korea, Taiwan, Singapore, Australia, Israel
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer NCT06989112 · Endometrial Cancer Drugs: Carboplatin, Docetaxel, Keytruda	Phase 3	Recruiting	2025-03	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Norway, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo NCT07069829 · ClinicalTrials.gov ↗ · Chronic Obstructive Pulmonary Disease	Observational	Recruiting	2025-12	Mexico, Taiwan, Egypt
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer NCT05061550 · Non-small Cell Lung Cancer Drugs: AZD0171, Carboplatin, Carboplatin/Paclitaxel	Phase 2	Recruiting	2022-04	Ireland, USA, France, Spain, Italy, Belgium, Portugal, Turkey, Canada, South Korea, Taiwan
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight NCT07784270 · Obesity or Overweight, Diabetes Mellitus, Type 2 Drug: Lenbelintide	Phase 3	Recruiting	2026-08	UK, USA, India, China, Germany, Spain, Poland, Canada, Japan, South Korea, Taiwan, Australia
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin NCT07662135 · Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease Drug: Elecoglipron	Phase 3	Recruiting	2026-07	UK, USA, India, China, Germany, Spain, Denmark, Turkey, Mexico, Japan, Taiwan
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF NCT07761117 · Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF) Drug: Elecoglipron	Phase 3	Recruiting	2026-08	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Sweden, Poland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment NCT07691970 · Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus Drug: Anifrolumab	Phase 3	Recruiting	2026-08	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure NCT06742723 · Chronic Kidney Disease and Hypertension Drug: Baxdrostat/dapagliflozin	Phase 3	Recruiting	2025-03	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel, Egypt
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen NCT05624450 · Viral Lung Infection and Acute Respiratory Failure Drug: Tozorakimab	Phase 3	Recruiting	2022-12	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel, Egypt
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) NCT07221253 · Biliary Tract Cancer Drugs: Durvalumab, Gemcitabine/Cisplatin, Rilvegostomig	Phase 3	Recruiting	2025-12	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6). NCT07735637 · Newly Diagnosed Multiple Myeloma (NDMM) Drugs: ASCT, AZD0120, Cyclophosphamide	Phase 3	Recruiting	2026-09	UK, USA, China, Germany, France, Spain, Italy, Denmark, Poland, Norway, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Egypt
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus NCT07784725 · Obesity or Overweight Drug: Lenbelintide	Phase 3	Recruiting	2026-08	USA, India, China, Germany, France, Italy, Poland, Czechia, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer NCT06350097 · Non-small Cell Lung Cancer Drugs: Dato-DXd, Osimertinib	Phase 3	Recruiting	2024-04	USA, India, China, Germany, France, Spain, Italy, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer NCT07218809 · Epithelial Ovarian Cancer Drugs: MIRV, Mirvetuximab Soravtansine, Paclitaxel	Phase 3	Recruiting	2025-12	Ireland, UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Switzerland, Czechia, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer NCT06467357 · Biliary Tract Cancer Drugs: Cisplatin, Durvalumab, Gemcitabine	Phase 3	Recruiting	2024-08	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study NCT07295821 · ClinicalTrials.gov ↗ · Lung Cancer Drug: Osimertinib	Phase 2	Recruiting	2026-04	China
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 NCT06219941 · Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer Drugs: Adrucil, Gemcitabine, Irinotecan	Phase 2	Recruiting	2023-12	UK, USA, China, Spain, Poland, Canada, Japan, South Korea, Taiwan, Singapore, Australia
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 NCT07431281 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer Drugs: Adrucil, Capecitabine, Leucovorin	Phase 3	Recruiting	2026-02	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043 · ClinicalTrials.gov ↗ · Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin) Drug: Rilvegostomig	Phase 1/2	Recruiting	2025-07	USA, Japan, South Korea, Australia
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia NCT06137118 · B-cell Acute Lymphoblastic Leukemia (B-ALL) Drug: Surovatamig	Phase 1/2	Recruiting	2023-12	UK, USA, China, Germany, France, Spain, Italy, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients NCT06549595 · Untreated Follicular Lymphoma Drugs: R-Chop, Surovatamig	Phase 3	Recruiting	2024-08	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Czechia, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT NCT07764978 · Newly Diagnosed Multiple Myeloma Drugs: AZD0120, Bortezomib, Cyclophosphamide	Phase 3	Recruiting	2026-06	UK, USA, Germany, France, Spain, Italy, Sweden, Denmark, Poland, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis NCT07276581 · Rheumatoid Arthritis	Phase 2	Recruiting	2025-12	UK, USA, China, Germany, Spain, Poland, Canada, Brazil, Mexico, Japan
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma NCT07681596 · Relapsed or Refractory Multiple Myeloma Drugs: Aldesleukin, Daratumumab	Phase 1/2	Recruiting	2026-07	USA, Australia
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05) NCT07711002 · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Drugs: Abiraterone, Darolutamide, Enzalutamide	Phase 3	Recruiting	2026-09	UK, USA, India, China, Germany, France, Spain, Italy, Poland, Switzerland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations NCT06357533 · Non-Small Cell Lung Cancer Drugs: Dato-DXd, Keytruda, Pembrolizumab	Phase 3	Recruiting	2024-04	UK, USA, India, China, Germany, Spain, Italy, Belgium, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) NCT07391657 · Relapsed Refractory Multiple Myeloma Drugs: AZD0120, Bortezomib, Carfilzomib	Phase 3	Recruiting	2026-02	UK, USA, China, Germany, France, Spain, Italy, Poland, Norway, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer NCT07205822 · Breast Cancer Drug: Dato-DXd	Phase 3	Recruiting	2025-10	USA, China, France, Spain, Italy, South Korea
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors NCT06005493 · Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma Drug: Rilvegostomig	Phase 1/2	Recruiting	2023-07	UK, USA, China, France, Netherlands, Japan, South Korea, Taiwan
MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab NCT07024706 · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) Drugs: Acalabrutinib, Venclexta, Venetoclax	Phase 2	Recruiting	2026-06	Ireland, UK, USA, Spain, Italy, Poland, Austria, Czechia, Brazil
Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours NCT07446855 · Solid Tumours Drug: Saruparib	Phase 1/2	Recruiting	2026-03	UK, USA, Spain, Japan, South Korea, Australia
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin NCT06677060 · Heart Failure Drug: Baxdrostat/dapagliflozin	Phase 3	Recruiting	2025-03	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Sweden, Denmark, Poland, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus NCT07662044 · Type 2 Diabetes Mellitus Drugs: Dapagliflozin, Elecoglipron	Phase 3	Recruiting	2026-07	USA, China, Spain, Denmark, Turkey, Japan, South Korea, Taiwan
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants NCT05835310 · Systemic Lupus Erythematosus Drug: Anifrolumab	Phase 3	Recruiting	2024-03	UK, USA, China, Germany, France, Spain, Italy, Poland, Portugal, Turkey, Canada, Brazil, Mexico, Japan
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin NCT07664553 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus Drug: Elecoglipron	Phase 3	Recruiting	2026-07	USA, India, China, Germany, Poland, Czechia, Canada, Japan, South Korea, Australia
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia NCT07109219 · B-cell Acute Lymphoblastic Leukemia (B-ALL)	Phase 1/2	Recruiting	2025-11	UK, USA, China, Spain, Canada, Japan, South Korea, Taiwan, Australia
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma NCT07123454 · B-cell Non-Hodgkin Lymphoma Drug: Surovatamig	Phase 1/2	Recruiting	2025-09	UK, USA, China, Italy, Japan, South Korea, Taiwan, Australia
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours NCT06795022 · Hepatocellular Carcinoma	Phase 1/2	Recruiting	2025-03	USA, China, Spain, Japan, South Korea, Taiwan
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer NCT07816666 · Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer Drugs: Bevacizumab, Torvutatug samrotecan	Phase 3	Recruiting	2026-09	USA, India, China, Germany, Spain, Italy, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer NCT07851025 · Epithelial Ovarian Cancer Drugs: Avastin, Bevacizumab, Torvutatug samrotecan	Phase 3	Recruiting	2026-09	UK, USA, India, China, Germany, France, Spain, Italy, Poland, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada NCT07143110 · ClinicalTrials.gov ↗ · Lung Neoplasms	Observational	Recruiting	2025-08	Canada
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) NCT06883305 · Chronic Obstructive Pulmonary Disease (COPD) Drug: Tezepelumab	Phase 3	Recruiting	2025-03	UK, USA, India, China, Germany, Spain, Italy, Denmark, Poland, Czechia, Canada, Brazil, Mexico, South Korea
Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care System NCT07361276 · ClinicalTrials.gov ↗ · Hypertension	Observational	Recruiting	2026-03	Brazil
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases NCT06512883 · ClinicalTrials.gov ↗ · Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES) Drugs: Benralizumab, Fasenra	Phase 3	Recruiting	2025-04	USA, India, France, Netherlands, Poland, Turkey, Canada, Brazil, Mexico, Israel
A Non-interventional, Prospective Study With Benralizumab NCT06422078 · ClinicalTrials.gov ↗ · Asthma, Bronchial	Observational	Recruiting	2024-07	Germany
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer NCT06879041 · Metastatic Castration-Resistant Prostate Cancer Drug: AZD2287	Phase 1	Recruiting	2025-03	USA, Australia
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) NCT07044336 · Endometrial Cancer, Malignant Solid Tumour Drugs: Adriamycin, Doxorubicin, Paclitaxel	Phase 3	Recruiting	2025-08	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Austria, Czechia, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD) NCT07624305 · Renal Insufficiency, Chronic Drug: Dapagliflozin	Phase 3	Recruiting	2026-09	UK, USA, India, China, Germany, France, Spain, Italy, Poland, Austria, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) NCT06103864 · Breast Cancer Drugs: Carboplatin, Dato-DXd, Durvalumab	Phase 3	Recruiting	2023-11	UK, USA, India, China, Germany, France, Spain, Italy, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT07402915 · Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Drugs: Itraconazole, Torvutatug samrotecan	Phase 1	Recruiting	2026-01	Ireland, Spain, Portugal
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease. NCT07753993 · Chronic Kidney Disease Drug: Elecoglipron	Phase 3	Recruiting	2026-08	UK, USA, India, China, Germany, France, Spain, Italy, Sweden, Denmark, Poland, Czechia, Norway, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE NCT06897930 · Lupus Erythematosus, Systemic Drugs: AZD0120, Cyclophosphamide, Fludarabine	Phase 1/2	Recruiting	2025-04	UK, USA, Canada, Australia
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies NCT05123482 · Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer Drugs: Palacaparib, Rilvegostomig, Saruparib	Phase 1/2	Recruiting	2021-10	UK, USA, China, Spain, Italy, Netherlands, Belgium, Poland, Canada, Japan, South Korea, Taiwan, Australia
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment NCT07444567 · Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES) Drugs: Benralizumab, Fasenra	Phase 3	Recruiting	2026-07	UK, USA, India, France, Italy, Netherlands, Belgium, Poland, Austria, Turkey, Canada, South Korea, Israel
Imjudo & Imfinzi PMS NCT06544629 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Observational	Recruiting	2025-04	South Korea
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer NCT06868277 · Carcinoma, Non-Small Cell Lung Drugs: Keytruda, Pembrolizumab, Rilvegostomig	Phase 3	Recruiting	2025-04	Ireland, UK, USA, China, Germany, France, Spain, Italy, Belgium, Switzerland, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Australia, Israel
NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations NCT06494540 · ClinicalTrials.gov ↗ · Non-squamous Metastatic Non-Small-Cell Lung Carcinoma	Observational	Recruiting	2024-06	Germany
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL NCT05952024 · Diffuse Large B-Cell Lymphoma Drugs: Acalabrutinib, Rituximab	Phase 2	Recruiting	2024-07	USA, Brazil, South Korea, Taiwan
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy NCT06129864 · Locally Advanced Head and Neck Squamous Cell Carcinoma Drug: Volrustomig	Phase 3	Recruiting	2023-12	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan
Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease NCT06531798 · ClinicalTrials.gov ↗ · Moderate to Severe COPD	Phase 4	Recruiting	2026-01	India
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2) NCT06960577 · ClinicalTrials.gov ↗ · Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate Drugs: Cisplatin, Doxorubicin, Durvalumab	Phase 2	Recruiting	2025-05	France, Spain, Italy, Netherlands, Canada, Brazil, Australia
First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer NCT07529717 · Metastatic Prostate Cancer	Phase 1/2	Recruiting	2026-05	USA, South Korea, Australia
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma NCT06106945 · Multiple Myeloma Drugs: Dexamethasone, Elranatamab, Pomalidomide	Phase 1/2	Recruiting	2023-12	UK, USA, China, Germany, France, Spain, Canada, Brazil, Japan, Australia
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC NCT06627647 · Non-squamous Non-small Cell Lung Cancer Drugs: Carboplatin, Cisplatin, Keytruda	Phase 3	Recruiting	2024-11	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations NCT07291037 · Non-small Cell Lung Cancer (NSCLC) Drugs: Dato-DXd, Docetaxel	Phase 3	Recruiting	2025-10	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Egypt
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC NCT07720284 · High-risk Muscle Invasive Urothelial Carcinoma Drugs: Dato-DXd, Durvalumab, Enfortumab Vedotin	Phase 3	Recruiting	2026-07	UK, USA, India, China, Germany, France, Spain, Italy, Poland, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer NCT06380751 · Advanced Breast Cancer Drugs: Abemaciclib, Anastrozole, Camizestrant	Phase 3	Recruiting	2024-08	UK, USA, India, China, Germany, France, Spain, Italy, Poland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis) NCT06455449 · Polymyositis, Dermatomyositis	Phase 3	Recruiting	2024-06	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma NCT05702229 · Gastric Cancer Drugs: Adrucil, Capecitabine, Folfox	Phase 2	Recruiting	2023-01	UK, USA, China, Spain, Japan, South Korea, Taiwan
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function NCT06307652 · Heart Failure and Impaired Kidney Function	Phase 3	Recruiting	2024-04	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Sweden, Poland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom NCT05557695 · Chronic Lymphocytic Leukemia, CLL Drug: Acalabrutinib	Observational	Recruiting	2022-10	UK
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy NCT05774951 · Breast Cancer, Early Breast Cancer Drugs: Anastrozole, Camizestrant, Exemestane	Phase 3	Recruiting	2023-03	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM NCT07667803 · Weight Management Drug: Elecoglipron	Phase 3	Recruiting	2026-06	UK, USA, India, China, Germany, Spain, Italy, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Observational Study Protocol: LIVER-R NCT06252753 · Hepatobiliary Cancers	Observational	Recruiting	2023-12	USA, Germany, France, Spain, Italy, Belgium, Switzerland, Austria, Norway, Portugal, Canada, Brazil, Japan, Taiwan, Singapore, Australia, Israel
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) NCT05850234 · Relapsed/Refractory Multiple Myeloma Drug: AZD0120	Phase 1/2	Recruiting	2023-07	USA
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event NCT07000357 · Cardiovascular Disease Drug: AZD0780	Phase 3	Recruiting	2025-06	UK, USA, India, China, Germany, France, Spain, Italy, Sweden, Denmark, Poland, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) NCT07611110 · Metastatic Castration-resistant Prostate Cancer Drugs: Abiraterone, Apalutamide, Cabazitaxel	Phase 3	Recruiting	2026-05	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Switzerland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer NCT07427394 · Advanced Breast Cancer Drugs: Atirmociclib, Camizestrant	Phase 2	Recruiting	2026-05	UK, USA
AZD5305 hADME in Patients With Advanced Solid Malignancies NCT06713369 · Locally Advanced or Metastatic Solid Tumor Drug: Saruparib	Phase 1	Recruiting	2025-04	UK
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids NCT06932263 · Asthma Drug: Tozorakimab	Phase 2	Recruiting	2025-03	USA, India, China, France, Spain, Italy, Turkey, Brazil, Japan, South Korea, Taiwan, Israel
Clarify HPP: Disease Burden of HPP Patients in China NCT07905287 · ClinicalTrials.gov ↗ · Hypophosphatasia (HPP)	Observational	Recruiting	2026-09	China
A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies NCT07606066 · Type 2 Diabetes	Observational	Recruiting	2026-05	USA, India, Poland, Turkey, Brazil
A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy NCT07241104 · ClinicalTrials.gov ↗ · Dilated Cardiomyopathy	Phase 1	Recruiting	2025-12	Netherlands
Study That Will Evaluate the Brazilian Population With COPD. NCT06780046 · ClinicalTrials.gov ↗ · COPD (Chronic Obstructive Pulmonary Disease)	Observational	Recruiting	2025-01	Brazil
Tezspire Cardiac Events PASS NCT06951867 · Cardiovascular Events, MACE Drug: Tezepelumab	Observational	Recruiting	2025-09	USA, Germany, France, Denmark
INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use NCT06314282 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE)	Observational	Recruiting	2024-10	China, Mexico, Taiwan, Egypt
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease NCT07571746 · Primary Membranous Nephropathy Drug: Surovatamig	Phase 2	Recruiting	2026-03	UK, USA, China, Germany, France, Spain, Italy, Belgium, Poland
Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM NCT07690436 · Transthyretin Amyloid Cardiomyopathy	Observational	Recruiting	2026-07	USA, Germany, Spain, Sweden, Portugal
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors NCT05797168 · Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer Drugs: Avastin, Bevacizumab, Carboplatin	Phase 1/2	Recruiting	2023-06	UK, USA, China, Germany, Spain, Turkey, Canada, Japan, South Korea, Taiwan, Australia, Israel

Showing the 100 most recently updated of 454 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

AstraZeneca in the EU trials register (CTIS)

25 trials · 1 in Ireland

Authorised or ongoing trials in the EU Clinical Trials Information System with AstraZeneca as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
The MAVRiC Study: A Phase II Study of Disease Risk Mutation-guided Finite Duration Acalabrutinib plus Venetoclax for Relapse in CLL/SLL after First-line Finite covalent BTKi plus BCL2i combination, with or without Obinutuzumab 2024-518858-17-00 · Neoplasms Drugs: Acalabrutinib, Venetoclax	Phase 2	Ongoing	Ireland + 5 more
A Randomised, Double‑Blind, Placebo‑Controlled, 2‑Cohort, Phase III Study of Saruparib Combined with Physician’s Choice of Androgen Receptor Pathway Inhibitor in Patients With Metastatic Hormone‑Sensitive Prostate Cancer, Previously Treated With Docetaxel or PSMA‑directed 177Lutetium‑Containing Therapy Without Disease Progression, and With Prostate‑Specific Antigen ≥ 0.2 ng/mL: EvoPAR Prostate‑05 2026-526275-38-00 · CTIS ↗ · Male Urogenital Diseases Drugs: Abiraterone, Darolutamide, Degarelix	Phase 3	Authorised	Poland, Hungary, France + 4 more
ROSY-S: Rollover Study for Participants Who have Completed a Previous Study with Anifrolumab (Saphnelo) and Are Assessed by the Investigator to Clinically Beneﬁt From Continued Treatment 2026-526419-13-00 · CTIS ↗ · Musculoskeletal Diseases Drug: Anifrolumab	Phase 3	Authorised	Netherlands, Belgium, Bulgaria + 10 more
A Phase III, Randomised, Double-blind, Study to Evaluate the Effect of Balcinrenone/Dapagliflozin Compared with Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease (Stage 3b and 4) 2026-526114-90-00 · CTIS ↗ · Cardiovascular Diseases Drug: Dapagliflozin	Phase 3	Ongoing	France, Germany, Austria + 6 more
A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment with AZD0120, an Autologous Dual Targeting Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible (TE NDMM) (DURGA-6) 2026-525367-40-00 · CTIS ↗ · Neoplasms Drugs: AZD0120, Lenalidomide, Melphalan	Phase 3	Authorised	Germany, Spain, Norway + 4 more
A Phase III Randomised, Double-Blind, Factorial Design Study to Assess the Effect of Fixed Dose Combination Laroprovstat/Rosuvastatin compared with Laroprovstat, Rosuvastatin, and Placebo on Low-Density Lipoprotein Cholesterol in Lipid-Lowering Treatment-Naïve Patients 2026-525642-30-00 · CTIS ↗ · Nutritional and Metabolic Diseases Drugs: AZD0780, Rosuvastatin	Phase 3	Authorised	Germany, Bulgaria, Hungary + 3 more
A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma (TROPION-Urothelial04). 2025-525030-57-00 · Neoplasms Drugs: Dato-DXd, Durvalumab, Enfortumab Vedotin	Phase 3	Ongoing	Italy, Poland, Spain + 2 more
A Multicenter, Open-Label, Phase II Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age with Systemic Lupus Erythematosus. 2025-524578-41-00 · Immune System Diseases Drug: Anifrolumab	Phase 2	Ongoing	Belgium, Portugal, Netherlands
A trial to learn how safe anifrolumab is, how it moves throughout the body over time, and how it affects the body of adults with systemic lupus erythematosus 2026-526171-32-00 · Immune System Diseases	Phase 1	Ongoing	Poland, Hungary
A Phase III Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against BCMA and CD19, Compared with Continuous Standard Therapy in Participants with NDMM Who Are Ineligible to Receive ASCT as Initial Therapy (DURGA-5). 2025-524014-29-00 · Neoplasms Drugs: AZD0120, Bortezomib, Daratumumab	Phase 3	Authorised	Poland, Italy, Denmark + 4 more
A Modular Open-label, Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Ascending Doses of AZD4956 as Monotherapy, and in Combination with Anti-Cancer Agents in Participants with Advanced/Metastatic Homologous Recombination Repair Defective Solid Tumours (PARTHENON) 2025-524171-22-00 · Neoplasms Drug: Saruparib	Phase 1	Ongoing	Spain
ROSY-F: Roll-Over Study for Participants Who Have Completed a Previous Study with Benralizumab (Fasenra) and Are Judged by the Investigator to Clinically Benefit from Continued Treatment 2025-523307-29-00 · Respiratory Tract Diseases Drug: Benralizumab	Phase 3	Ongoing	Denmark, Belgium, France + 4 more
A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)) (ARGiNAUT) 2025-525016-41-00 · Respiratory Tract Diseases	Phase 2	Ongoing	Poland, Hungary, Netherlands + 7 more
A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults with Antibody-mediated Kidney Disease 2025-524139-38-00 · Immune System Diseases Drug: Surovatamig	Phase 2	Authorised	France, Germany, Italy + 3 more
A Phase II, Randomized, Double-blind, 3-Period Cross-over, Dose‑ranging Study to Assess the Efficacy and Safety of Glycopyrronium (GP) versus Placebo in Participants of 4 to Less than 12 Years of Age with Asthma Receiving Background Budesonide and Formoterol Fumarate (BFF) (FAROS) 2025-524914-26-00 · Respiratory Tract Diseases	Phase 2	Ongoing	Czechia, Poland, Hungary
Phase III, Open-label Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, Efficacy, and Immunogenicity of Benralizumab in Children with Eosinophilic Disease (CLIPS) 2023-508533-14-00 · Immune System Diseases Drug: Benralizumab	Phase 3	Ongoing	Poland, Netherlands, France
A Master Protocol of a Phase II, Open-label, Multicenter, Global Platform Study to Evaluate the Safety and Efficacy of Immunotherapy With or Without Other Anticancer Drugs in Participants with Unresectable Stage III Non-small Cell Lung Cancer Planning to Undergo Concurrent Chemoradiotherapy (AQUARIUS) 2025-523599-21-00 · Neoplasms Drugs: Carboplatin, Cisplatin, Infliximab	Phase 2	Authorised	Spain, Germany
A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer (ACTIVATED-4-PC) 2025-520626-37-00 · Neoplasms	Phase 1	Ongoing	Belgium, Spain, Poland + 2 more
A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma (DURGA-4) 2025-523285-25-00 · CTIS ↗ · Neoplasms Drugs: AZD0120, Bortezomib, Carfilzomib	Phase 3	Ongoing	Norway, Poland, Spain + 3 more
A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (ALTAIR) 2024-519786-22-01 · CTIS ↗ · Neoplasms Drugs: Ramucirumab, Rilvegostomig	Phase 1	Ongoing	Germany, Spain, France + 4 more
A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD9793, a T cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants with Advanced or Metastatic Solid Tumours (RHEA-1) 2024-516698-56-00 · CTIS ↗ · Neoplasms	Phase 1	Authorised	Spain
A Phase IIb, Randomised, Multicentre, Double-Blind Study to Evaluate the Effect of Baxdrostat in Combination with Dapagliflozin Compared with Baxdrostat on Albuminuria in Participants with Chronic Kidney Disease and High Blood Pressure 2025-522407-23-00 · CTIS ↗ · Cardiovascular Diseases Drugs: Baxdrostat, Dapagliflozin	Phase 2	Ongoing	Spain, Bulgaria
A Phase IIa, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Assess the Efficacy, Safety, and Tolerability of AZD4144 in Participants with Sepsis-associated Acute Kidney Injury (SERENIA) 2025-522232-13-00 · CTIS ↗ · Not possible to specify Drug: AZD4144	Phase 2	Ongoing	Germany, France, Spain + 6 more
A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants with Advanced Haematologic Malignancies with KMT2Ar, NPM1m, or Other Genotypes Associated with HOX Overexpression 2025-521299-76-00 · CTIS ↗ · Neoplasms	Phase 1	Ongoing	Germany, Italy, Denmark
A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician’s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01) 2024-518777-34-00 · CTIS ↗ · Neoplasms Drugs: Doxorubicin, Paclitaxel	Phase 3	Ongoing	Italy, Netherlands, Lithuania + 12 more

Drugs in AstraZeneca trials

206 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 166 more in the trial list above.

By trial register

Register	Trials	Recruiting
Clinical trials in USA	294	143
Clinical trials in China	226	120
Clinical trials in Spain	221	104
Clinical trials in South Korea	202	94
Clinical trials in UK	196	99
Clinical trials in Japan	195	91
Clinical trials in Canada	190	88
Clinical trials in Germany	188	95
Clinical trials in Italy	180	82
Clinical trials in France	173	76
Clinical trials in Taiwan	166	78
Clinical trials in Poland	161	72
Clinical trials in Brazil	155	77
Clinical trials in Australia	144	81
Clinical trials in Turkey	114	55
Clinical trials in India	103	49
Clinical trials in Belgium	102	35
Clinical trials in Netherlands	87	34
Clinical trials in Israel	67	27
Clinical trials in Mexico	67	30
Clinical trials in Denmark	59	34
Clinical trials in Austria	54	23
Clinical trials in Czechia	51	25
Clinical trials in Sweden	49	25
Clinical trials in Portugal	33	11
Clinical trials in Switzerland	26	8
Clinical trials in Singapore	24	10
Clinical trials in Norway	18	8
Clinical trials in Egypt	14	11
Clinical trials in Ireland	9	5
EU register (CTIS)	25	—

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Breast Cancer

Sponsor	Trials
Fudan University	49
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	21
Second Affiliated Hospital, Zhejiang University, School of Medicine	18
University Health Network, Toronto	16
Institut du Cancer de Montpellier - Val d'Aurelle	16
Sunnybrook Health Sciences Centre	15
Shengjing Hospital	15
European Institute of Oncology	14
Pfizer	12
The Netherlands Cancer Institute	12

Sponsors with the most current trials registered for this condition.

Questions about AstraZeneca trials

How many clinical trials does AstraZeneca sponsor?

AstraZeneca is the lead sponsor of 454 current trials on ClinicalTrials.gov in our USA, China, Spain, South Korea, UK, Japan, Canada, Germany, Italy, France, Taiwan, Poland, Brazil, Australia, Turkey, India, Belgium, Netherlands, Israel, Mexico, Denmark, Austria, Czechia, Sweden, Portugal, Switzerland, Singapore, Norway, Egypt and Ireland registers, and 25 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are AstraZeneca trials recruiting?

Yes. 229 of its 454 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is AstraZeneca testing?

Its current trials name 206 drugs and biologicals as interventions. The most frequent are Durvalumab (71), Carboplatin (45), Cisplatin (37), Rilvegostomig (32) and Paclitaxel (30). The number in brackets is how many of its trials name each drug.

Does AstraZeneca have clinical trials in Ireland?

Yes. 9 trials in our Ireland register (ClinicalTrials.gov), and 1 trial in the EU register (CTIS) with a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.